Regnite® (gabapentin enacarbil) Extended Release Tablets received marketing approval in Japan for the treatment of moderate-to-severe primary restless legs syndrome (RLS) in January 2012 and in April 2012 the Central Social Insurance Medical Council (the CSIMC, also known as Chuikyo), which is responsible for recommending the National Health Insurance (NHI) price for pharmaceutical products in Japan, approved the reimbursement price of 98.50 yen per 300 mg tablet of Regnite proposed by the Drug Price Organization. Regnite and its NHI price was listed in the NHI drug formulary on April 17, 2012. The approved daily dose of Regnite for the treatment of moderate-to-severe primary restless legs syndrome is 600 mg per day.